CampETEC Hyperimmune Bovine Colostrum (HBC) - Trial NCT06122870
Access comprehensive clinical trial information for NCT06122870 through Pure Global AI's free database. This Phase 1 trial is sponsored by Johns Hopkins Bloomberg School of Public Health and is currently Not yet recruiting. The study focuses on Healthy Volunteer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Johns Hopkins Bloomberg School of Public Health
Timeline & Enrollment
Phase 1
Dec 01, 2023
Feb 01, 2025
Primary Outcome
Incidence of Adverse Events,Number of participants with campylobacteriosis patterns
Summary
Gastrointestinal infections cause significant morbidity in the form of acute diarrheal
 illness in the United States (US) and among travelers to low- and middle-income countries
 (LMICs). One approach is to use passive protection (antibodies) to prevent infection. The
 purpose of this study are to assess the safety and tolerability of serum-derived bovine
 immunoglobulins in healthy adult subjects when orally administered and to estimate protective
 efficacy of those preparations against moderate-severe diarrhea upon challenge with
 Campylobacter C. jejuni strain CG8421.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06122870
Non-Device Trial